Sugi Predict

Sugi Predict / Compounds / SCHEMBL222671

SCHEMBL222671

SCHEMBL222671

CC(C)(C)OC(=O)N1C(C=O)COC1(C)C

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SPHK1 Q9NYA1 1/20 0.50
▸ BRD4 O60885 1/20 0.39
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ DDB1 Q16531 1/20 0.34
▸ CRBN Q96SW2 1/20 0.34
▸ NR1H2 P55055 2/20 0.34
▸ HSD11B2 P80365 1/20 0.33
▸ RECQL P46063 1/20 0.32
▸ CTSK P43235 1/20 0.32
▸ EPHX2 P34913 1/20 0.31
▸ HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209164 1.00 SPHK1 (0.50) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL222670 1.00 SPHK1 (0.50) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL1840177 0.87 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL1370603 0.87 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL1370602 0.87 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL11959795 0.86 SPHK1 (0.44) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL12507489 0.86 SPHK1 (0.44) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL6444864 0.85 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL13964503 0.85 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL2615731 0.85 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024112637-A1 NOVEL METHODS FOR CHEMICAL SYNTHESIS OF GLYCOSYLATED SPHINGOSINES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-05-30 — — WO claimed
EP-4737470-A2 C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF Zikani Therapeutics, Inc. (US) 2026-05-06 — — EP disclosed
WO-2026087635-A1 DIHYDRO BENZOXAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 — — WO disclosed
EP-4733305-A2 PYRROLE COMPOUNDS Aligos Therapeutics, Inc. (US) 2026-04-29 — — EP disclosed
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof CIT THERAPEUTICS, INC. (US) 2026-04-28 — — US disclosed
US-12599582-B2 Pyrrole compounds ALIGOS THERAPEUTICS, INC. (US) 2026-04-14 — — US disclosed
EP-3947349-B1 PYRROLE COMPOUNDS ALIGOS THERAPEUTICS INC (US) 2026-03-11 — — EP disclosed
US-12552825-B2 C10-alkylene substituted 13-membered macrolides and uses thereof Zikani Therapeutics , Inc. (US) 2026-02-17 — — US disclosed
EP-3883647-B1 C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF ZIKANI THERAPEUTICS INC (US) 2026-02-11 — — EP disclosed
US-20260035402-A1 C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF ZIKANI THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
US-6645981-B2 For therapy of microbial infection THE PROCTER & GAMBLE COMPANY 2003-11-11 — — US disclosed
US-20030176460-A1 Piperidine compounds for use as ccr-3 inhibitors NOVARTIS AG (CH) 2003-09-18 — — US disclosed
EP-1341781-A1 ANTIMICROBIAL QUINOLONES THE PROCTER & GAMBLE COMPANY (US) 2003-09-10 — — EP disclosed
EP-1303488-A1 PIPERIDINE COMPOUNDS FOR USE AS CCR-3 INHIBITORS Novartis AG (CH) 2003-04-23 — — EP disclosed
US-20030008894-A1 Antimicrobial quinolones, their compositions and uses THE PROCTER & GAMBLE COMPANY 2003-01-09 — — US disclosed
WO-2002102775-A1 DERIVATIVES OF 3-PHENYL-N-(2- (4-BENZYL) PIPERIDIN-1-YL)-ETHYL)-ACRYLAMID WITH CCR-3 RECEPTOR ANTAGONISTIC ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATIONS AND ALLERGIC CONDITIONS NOVARTIS AG (CH) 2002-12-27 — — WO disclosed
EP-1224171-A1 BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-07-24 — — EP disclosed
WO-2002048138-A1 ANTIMICROBIAL QUINOLONES THE PROCTER & GAMBLE COMPANY (US) 2002-06-20 — — WO disclosed
WO-2002004420-A1 PIPERIDINE COUMPOUNDS FOR USE AS CCR-3 INHIBITORS NOVARTIS AG (CH) 2002-01-17 — — WO disclosed
WO-2001027084-A1 BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2001-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035402-A1 C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF MALT1, CCR10, CYP51A1 SPHK1 1706/4885BRD4 2138/4885CHRM2 3394/4885
US-12552825-B2 C10-alkylene substituted 13-membered macrolides and uses thereof MALT1, NR3C2, MRPL21 SPHK1 1443/4885BRD4 3090/4885CHRM2 2163/4885
US-12599582-B2 Pyrrole compounds PEF1, CYP4F8, CYP2C19 SPHK1 2817/4885BRD4 4152/4885CHRM2 4197/4885
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof SUMO1, SUMO3, PSMB6 SPHK1 4465/4885BRD4 485/4885CHRM2 3237/4885
US-20030176460-A1 Piperidine compounds for use as ccr-3 inhibitors CCR1, CCR3, CCR4 SPHK1 1170/4885BRD4 162/4885CHRM2 1653/4885
US-20030008894-A1 Antimicrobial quinolones, their compositions and uses QARS1, NQO2, Q6ZSR9 SPHK1 4612/4885BRD4 1366/4885CHRM2 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.